Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Xalkori | Crizotinib | ROS1-positive advanced non-small cell lung cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rozlytrek | Entrectinib | ROS1-positive NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rosiver | Ivermectin | Rosacea | List with criteria/condition | Complete | ||
| Apprilon | Doxycycline monohydrate | Rosacea | Do not list | Complete | ||
| Finacea | Azelaic acid | Rosacea | List | Complete | ||
| Vraylar | cariprazine | Schizophrenia | Do not reimburse | Complete | ||
| Rexulti | Brexpiprazole | schizophrenia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Saphris | Asenapine | Schizophrenia | Do not list | Complete | ||
| Latuda | Lurasidone | Schizophrenia | Do not list | Complete | ||
| Latuda | Lurasidone | Schizophrenia | List with criteria/condition | Complete |
Last Updated : April 27, 2024